title: IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.
abstract: Typically, botulinum toxin injections for blepharospasm or cervical dystonia (CD) are administered at approximately 3-month intervals, reflecting concerns that shorter intervals might increase the risk of adverse events (AEs) and development of neutralizing antibodies. These post-hoc analyses investigated flexible incobotulinumtoxinA (Xeomin®) injection intervals (6-20 weeks) in patients with blepharospasm or CD. Patients received up to 6 injections at intervals ≥ 6 weeks, as determined by physician assessment upon patient request. The blepharospasm study permitted flexible doses (≤ 50 U/eye). The CD study employed fixed dosing using incobotulinumtoxinA 120 U, 240 U, or placebo for the first treatment followed by subsequent randomization to 120 U or 240 U for the extension period. Standard safety assessments were performed. Intervals <12 weeks were employed in 207 of 461 (44.9%) treatment cycles for blepharospasm and in 369 of 821 (44.9%) treatment cycles for CD. The most frequent AEs were eyelid ptosis and dry eyes in patients treated for blepharospasm, and dysphagia and neck pain in patients with CD. AE frequency and severity were similar for intervals <12 weeks and ≥ 12 weeks in both studies. In conclusion, repeated incobotulinumtoxinA injections employing flexible intervals (6-20 weeks) per patients' needs were well tolerated. No additional safety concerns were observed with <12-week intervals compared with ≥ 12-week intervals.
authors.affiliation: Movement Disorders Center of Arizona, 9590 E. Ironwood Square Drive, Suite 225, Scottsdale, AZ 85258, USA. Electronic address: vevidente@movementdisorders.us.
authors.forename: Virgilio Gerald H
authors.initials: VG
authors.lastname: Evidente
authors.affiliation: The Parkinson's and Movement Disorder Institute, 9940 Talbert Avenue, Fountain Valley, CA 92708, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Truong
authors.affiliation: Department of Neurology, Baylor College of Medicine, Smith Tower, 18th Floor, 6550 Fannin, Suite 1801, Houston, TX 77030, USA.
authors.forename: Joseph
authors.initials: J
authors.lastname: Jankovic
authors.affiliation: Department of Neurological Sciences, Rush University Medical Center, 1725 West Harrison Street Suite 755, Chicago, IL 60612, USA.
authors.forename: Cynthia L
authors.initials: CL
authors.lastname: Comella
authors.affiliation: Merz Pharmaceuticals GmbH, Eckenheimer Landstrasse 100, 60318 Frankfurt, Germany.
authors.forename: Susanne
authors.initials: S
authors.lastname: Grafe
authors.affiliation: Merz Pharmaceuticals GmbH, Eckenheimer Landstrasse 100, 60318 Frankfurt, Germany.
authors.forename: Angelika
authors.initials: A
authors.lastname: Hanschmann
mesh_terms: D001764:Blepharospasm / Q000188:drug therapy*; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D017063:Outcome Assessment, Health Care; D012720:Severity of Illness Index; D013997:Time Factors; D014103:Torticollis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A; C545476:incobotulinumtoxinA
keywords: Blepharospasm; Botulinum toxin; Cervical dystonia; IncobotulinumtoxinA; Patient satisfaction; Xeomin®